- $50,000* for Selective Inhibition of Nuclear Export as a Novel Therapeutic Strategy in AML
Julia Etchin, PhD - Dana-Farber Cancer Institute
To examine the current treatments for Acute Myelogenous Leukemia (AML), which often fail to induce long-term remission. Knowledge gained from this study will make a significant contribution toward identifying highly active targeted treatments for AML that are less toxic to normal tissues.
$50,000* for Identification and Validation of New Therapeutic Targets in Pediatric Leukemia Through an Aneuploidy-based Synthetic Lethality Screen
Dana-Farber Cancer Institute; David Pellman, M.D.
Research of Trisomy 8, which is abnormal number of chromosomes, that is present in 15-20% of cases of AML and MDS. Data is being analyzed to determine which genes selectively kill trisomy 8 AML cell lines.
$50,000* for Development of An Innovative Treatment Strategy for Neuroblastoma and Other Pediatric Tumors: A Novel Phospholipid Ester Analogue and its Multifunctional Cancer-targeting Nanoconstruct
Mario Otto, M.D., PhD - University of Wisconsin-Madison
Study will look at the molecule NM404 to ascertain if NM404 can target and kill neuroblastoma cells or other forms of childhood cancer cells, and to evaluate if this compound could be a new potent treatment drug.
$50,000* for Development of Targeted Therapies in High Risk Childhood Acute Lymphoblastic Leukemia
The Children’s Hospital of Philadelphia; Sarah Tasian, M.D.
Research will focus on studying blood and bone marrow samples from children with certain types of high-risk Acute Lymphoblastic Leukemia (ALL) with the goal of improving our understanding of the functional consequences of specific genetic mutations. Through this work, she hopes to improve understanding of the critical biologic mechanisms involved in these leukemias to help identify new targeted therapies for children with high-risk ALL.